SeaStar Medical meets Nasdaq listing requirements and focuses on developing therapies with promising results

From GlobeNewswire: 2025-07-02 16:25:00

Medical Holding Corporation (Nasdaq: ICU) has met Nasdaq’s $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. SeaStar Medical CEO, Eric Schloff, is excited to focus on commercializing QUELIMMUNE and developing therapies for critically ill patients. QUELIMMUNE has shown a 77% survival rate in patients compared to historical data, reducing the loss of life by 50%. SeaStar Medical’s Selective Cytopheretic Device therapy is being evaluated in a pivotal trial for adults with Acute Kidney Injury (AKI) in the ICU. This unique therapy targets hyperinflammation and immune cells to promote organ recovery and prevent dialysis dependency.



Read more at GlobeNewswire: SeaStar Medical Announces Positive Nasdaq Listing